目次

Table of Content

1. Introduction To Antibody Drug Conjugates
1.1 Overview
1.2 Mechanism Of Antibody Drug Conjugates
1.3 Advantages Of Antibody Drug Conjugates
1.4 Applications Of Antibody Drug Conjugates In Cancer

2. Generations Of Lymphoma Antibody Drug Conjugates
2.1 Lymphoma Antibody Drug Conjugates - Evolution
2.2 Next Generation Antibody Drug Conjugates Prospects

3. Approved Lymphoma Antibody Drug Conjugates By Brand Name, Company and Indication

4. Global Lymphoma Antibody Drug Conjugates Market Outlook
4.1 Current Market Scenario
4.2 Global Lymphoma Antibody Drug Conjugates Market Trends and Development
4.3 Future Growth Avenues

5. Lymphoma Antibody Drug Conjugates Research and Market Trends By Region
5.1 US
5.2 China
5.3 Europe
5.4 Japan
5.5 Australia
5.6 UK
5.7 Canada
5.8 South Korea

6. Approved Lymphoma Antibody Drug Conjugates - Dosage Patent, Price and Sales Analysis (2020 - 2025)
6.1 Adcetris
6.1.1 Overview, Availability and Patent Insight
6.1.2 Pricing and Dosage Insight
6.1.3 Sales Analysis 6.2 Polivy
6.2.1 Overview, Availability and Patent Insight
6.2.2 Pricing and Dosage Insight
6.2.3 Sales Analysis 6.3 Zynlonta
6.3.1 Overview, Availability and Patent Insight
6.3.2 Pricing and Dosage Insight
6.3.3 Sales Analysis

7. Global Lymphoma Antibody Drug Conjugates Clinical Trials Overview
7.1 By Phase
7.2 By Indication
7.3 By Company
7.4 By Fast Track and Orphan Status
7.5 By Country

8. Global Lymphoma Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase I
8.4 Phase I/II
8.5 Phase II
8.6 Phase III

9. Marketed Lymphoma Antibody Drug Conjugates Clinical Trials Insight By Company, Country, Indication and Phase

10. Cancer Antibody Drug Conjugates Development Platforms By Company

11. Lymphoma Antibody Drug Conjugates Combination Therapies

12. Global Lymphoma Antibody Drug Conjugates Market Overview
12.1 Key Market Growth Drivers
12.2 Challenges For Market Growth

13. Competitive Landscape
13.1 ABL Bio
13.2 ADC Therapeutics
13.3 AstraZeneca
13.4 CStone Pharmaceuticals
13.5 Iksuda Therapeutics
13.6 Immunogen
13.7 Merck
13.8 Pfizer
13.9 Takeda
13.1 0 Tubulis GmbH

List of Figures & Tables
Figure 1-1: Antibody Drug Conjugates - General Working Mechanism
Figure 1-2: Advantages of Antibody Drug Conjugates
Figure 2-1: Cancer Antibody Drug Conjugates - Opportunities for Next-Generation Development
Figure 4-1: Global - Lymphoma Antibody Drug Conjugates Market (US$ Million), 2020-2025
Figure 4-2: Global - Lymphoma Antibody Drug Conjugate Market (US$ Million), H1’2025
Figure 4-3: Global - Lymphoma Antibody Drug Conjugate Sales by Drug (US$ Million), H1’2025
Figure 4-4: Global - Lymphoma Antibody Drug Conjugate Market Share by Drugs (%), H1’2025
Figure 4-5: Global - Lymphoma Antibody Drug Conjugate Sales by Drug (US$ Million), 2024
Figure 4-6: Global - Lymphoma Antibody Drug Conjugate Market Share by Drugs (%), 2024
Figure 4-7: Global - Lymphoma Antibody Drug Conjugate Market (US$ Million), Q1-Q4’2024
Figure 4-8: Global - Lymphoma Antibody Drug Conjugate Market by Drug (US$ Million), 2023
Figure 4-9: Global - Lymphoma Antibody Drug Conjugate Market Share by Drugs (%), 2023
Figure 4-10: 202207147 Phase 2 (NCT05410418) Study - Initiation and Completion Year
Figure 4-11: NCI-2022-05221 Phase 2 (NCT05453396) Study - Initiation and Completion Year
Figure 4-12: 20-404 Phase 2 (NCT04676360) Study - Initiation and Completion Year
Figure 4-13: LIGHTBEAM-U01 Phase 2 (NCT04676360) Study - Initiation and Completion Year
Figure 4-14: waveLINE-003 Phase 2/3 (NCT05139017) Study - Initiation and Completion Year
Figure 4-15: waveLINE-010 Phase 3 (NCT06717347) Study - Initiation and Completion Year
Figure 4-16: waveLINE-007 Phase 2 (NCT05406401) Study - Initiation and Completion Year
Figure 4-17: waveLINE-006 Phase 2 (NCT05458297) Study - Initiation and Completion Year
Figure 4-18: SUNMO Phase 3 (NCT05171647) Study - Initiation and Completion Year
Figure 4-19: Global - Cancer Antibody Drug Conjugate Market Forecast (US$ Billion), 2026 - 2030
Figure 4-20: Lymphoma Antibody Drug Conjugates - Future Opportunities
Figure 6-1: Adcetris - Approval Year by Region
Figure 6-2: US - Adcetris FDA Approval Year by Indication
Figure 6-3: Japan - Adcetris PMDA Approval Year by Indication
Figure 6-4: US - Adcetris Orphan Drug Designation Approval Year by Indication
Figure 6-5: Adcetris - Patent Expiration by Region
Figure 6-6: Adcetris - Cost of 50 mg Supply in US (US$), October’2025
Figure 6-7: Adcetris - Global Annual Sales (US$ Million), 2020-2025
Figure 6-8: Adcetris - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 6-9: Adcetris - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 6-10: Polivy - Approval Year by Region
Figure 6-11: Polivy - Orphan Drug Designation Approval Year by Region
Figure 6-12: US - Polivy Orphan Drug Designation Approval and Exclusivity Year
Figure 6-13: Polivy - Cost of Supply in US and Europe (US$), October’2025
Figure 6-14: Polivy - Global Sales Values (US$ Million), 2020-2025
Figure 6-15: Polivy - Global Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 6-16: Polivy - Global Sales By Region (%), H1’2025
Figure 6-17: Polivy - Global Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 6-18: Polivy - Global Sales By Region (US$ Million), 2024
Figure 6-19: Polivy - Global Sales By Region (%), 2024
Figure 6-20: Polivy - US Annual Sales Values (US$ Million), 2020-2025
Figure 6-21: Polivy - US Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 6-22: Polivy - US Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 6-23: Polivy - Europe Annual Sales Values (US$ Million), 2020-2025
Figure 6-24: Polivy - Europe Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 6-25: Polivy - Europe Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 6-26: Polivy - Japan Annual Sales Values (US$ Million), 2020-2025
Figure 6-27: Polivy - Japan Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 6-28: Polivy - Japan Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 6-29: Polivy - ROW Annual Sales Values (US$ Million), 2020-2025
Figure 6-30: Polivy - ROW Quarterly Sales Values (US$ Million), Q1 and Q2’2025
Figure 6-31: Polivy - ROW Quarterly Sales Values (US$ Million), Q1-Q4’2024
Figure 6-32: Zynlonta - FDA and EMA Approval Years
Figure 6-33: Zynlonta - FDA and EMA Orphan Drug Designation Years
Figure 6-34: Zynlonta - Cost of 10 mg Supply In US and Europe (US$), October’2025
Figure 6-35: Zynlonta - Global Annual Sales (US$ Million), 2021-2025
Figure 6-36: Zynlonta - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 6-37: Zynlonta - Global Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 7-1: Global - Lymphoma Antibody Drug Conjugate In Clinical Trials By Phase, 2025 Till 2030
Figure 7-2: Global- Lymphoma Antibody Drug Conjugate In Clinical Trials By Indication, 2025 Till 2030
Figure 7-3: Global - Lymphoma Antibody Drug Conjugate In Clinical Trials By Company, 2025 Till 2030
Figure 7-4: Global - Lymphoma Antibody Drug Conjugate In Clinical Trials By Fast Track and Orphan Status, 2025 Till 2030
Figure 7-5: Global - Lymphoma Antibody Drug Conjugate In Clinical Pipeline By Country, 2025 Till 2030
Figure 10-1: Proprietary ADC Technology - Seagen
Figure 10-2: ALE.P02 and ALE.P03 - Alentis Therapeutics
Figure 10-3: TRAAC - Tallac Therapeutics
Figure 10-4: ATAC - Heidelberg Pharma
Figure 10-5: Tub-tagandreg; and P5 - Tubulis
Figure 11-1: Lymphoma - Approved Antibody Drug Conjugate Combinations
Figure 12-1: Global Lymphoma Antibody Drug Conjugates Market - Drivers and Opportunities
Figure 12-2: Global Lymphoma Antibody Drug Conjugates Market - Key Challenges and Strategic Solutions
Table 2-1: Lymphoma - Approved Second Generation Antibody Drug Conjugates
Table 2-2: Lymphoma - Approved Third Generation Antibody Drug Conjugates
Table 3-1: Approved Lymphoma Antibody Drug Conjugates, October’2025
Table 4-1: Cancer Antibody Drug Conjugates - Recent Collaborations
Table 4-2: Cancer Antibody Drug Conjugates - Companies Securing Funding For Clinical Development
Table 4-3: Lymphoma - Approved Antibody Drug Conjugates
Table 5-1: US - Approved Lymphoma Antibody Drug Conjugates, October’2025
Table 5-2: China - Approved Lymphoma Antibody Drug Conjugates, October’2025
Table 5-3: EU - Approved Lymphoma Antibody Drug Conjugates, October’2025
Table 5-4: Japan - Approved Lymphoma Cancer Antibody Drug Conjugates, October’2025
Table 5-5: Australia - Approved Cancer Antibody Drug Conjugates, October’2025
Table 5-6: UK - Approved Antibody Drug Conjugates, October’2025
Table 5-7: Canada - Approved Cancer Antibody Drug Conjugates, October’2025
Table 6-1: Adcetris - Recommended Dosage
Table 11-1: Lymphoma - Ongoing Antibody Drug Conjugate Combination Clinical Trials